La cadena de opciones muestra datos clave de las opciones de acciones de GlycoMimetics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para GlycoMimetics..

GlycoMimetics (NASDAQ:GLYC) Bolsa, Cadena de Opciones

GlycoMimetics

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

GlycoMimetics Inc

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Tuesday.
The Dow traded down 0.11% to 42,341.64 while the NASDAQ rose 0.85% to 18,724.32. The S&amp;P 500 also rose, gaining, 0.35% to 5,843.93.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research">Jim Cramer: &#8216;Avoid&#8217; This Consumer Cyclical Stock, Buy Lam Research</a>
Leading and Lagging Sectors Communication services shares rose by 1.5% on Tuesday.
In trading on Tuesday, utilities shares fell by 1.8%.
Top Headline
Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) shares fell around 5% on Tuesday after it reported third-quarter FY24 results.
Adjusted EPS of $2.04 topped the consensus of $1.66. Midstream segment adjusted pre-tax income stood at $672 million, vs. $753 million in the second quarter of FY24, owing to seasonal maintenance costs and lower equity earnings.
The Chemicals segment adjusted pre-tax income stood at $342 million versus $222 million in the prior quarter, led by higher margins and lower costs.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares shot up 172% to $0.4608 after the company announced it will merge with Crescent Biopharma and secured $200 in funding to advance its oncology pipeline.</li>
<li>Shares of BIO-key International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) got a boost, surging 60% to $1.08 after the company announced it received a $910K order from a long-time financial services customer to upgrade its biometric customer identification technology.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares were also up, gaining 46% to $81.57 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) shares dropped 63% to $0.4655 after the company priced an $11.1 million public offering at $1.26 per unit.</li>
<li>Shares of TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) were down 31% to $87.61 after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue guidance with its midpoint below estimates.</li>
<li>Janus International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBI#NYSE">JBI</a>) was down, falling 32% to $7.00 after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $67.36 while gold traded up 1% at $2,782.00.
Silver traded up 1.5% to $34.50 on Tuesday, while copper fell 0.1% to $4.3595.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 slipped 0.57%, Germany's DAX fell 0.27% and France's CAC 40 slipped 0.61%. Spain's IBEX 35 Index fell 0.91%, while London's FTSE 100 fell 0.80%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index gaining 0.49%, China's Shanghai Composite Index falling 1.08% and India's BSE Sensex surging 0.45%.
Economics
<ul>
<li>The number of job openings declined by 418,000 to 7.443 million in September versus a revised 7.861 million in the previous month and below market estimates of 7.99 million.</li>
<li>The FHFA house price index rose 0.3% in August, above market estimates of a 0.2% rise.</li>
<li>The S&amp;P CoreLogic Case-Shiller home price index rose 5.2% year-over-year in August versus a 5.9% gain in July.</li>
<li>U.S. wholesale inventories declined by 0.1% month-over-month to $905 billion in September compared to revised 0.2% gain in the earlier month.</li>
<li>The U.S. trade deficit increased to $108.2 billion in September from the $94.2 billion gap in the previous month.</li>
<li>The Dallas Fed general business activity index for Texas&#8217; service sector climbed to 2 in October compared to a reading of -2.6 in the prior month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41598309/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

BKYI

EFSH

GLYC

TMDX

Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results

GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares are moving higher on Tuesday after the company announced it will merge with Crescent Biopharma. The company also said it secured $200 million in funding to advance <a href="https://www.benzinga.com//node/41595830">its oncology pipeline</a>.
What To Know: GlycoMimetics has entered into an acquisition agreement with privately held biotech firm Crescent BioPharma. The combined company, which will operate under the name Crescent Biopharma, Inc., will focus on advancing Crescent Biopharma's current solid tumor portfolio, including its lead therapies CR-001, CR-002 and CR-003.
In support of the merger, a group of investors has agreed to purchase $200 million in the combined company&#8217;s common stock and pre-funded warrants. The purpose of the funding is to support operations through 2027, including further developing lead therapeutic treatments.
The merger transaction is anticipated to close in the second quarter of 2025, with the financing transaction expected to close immediately afterward.
Under the acquisition agreement, pre-acquisition GlycoMimetics stockholders will hold about 3.1% of the combined company, while pre-acquisition Crescent stockholders, including those involved in pre-closing financing, will own roughly 96.9%.
&#8220;We are confident that our transaction with Crescent represents a significant opportunity for GlycoMimetics and its stockholders,&#8221; said Harout Semerjian, CEO of GlycoMimetics. 
&#8220;This transaction is the result of a comprehensive strategic review, and with additional funding for Crescent&#8217;s portfolio of novel biologics, we believe the company is well-positioned to carry forward the mission of seeking to improve the lives of patients.&#8221;
GlycoMimetics stock is trading on above-average volume Tuesday. The company&#8217;s average session volume over the past 100 days is 1.05 million, but Tuesday&#8217;s trading volume was around 856 million at the time of publication. 
Related Link: <a href="https://www.benzinga.com/news/24/10/41582814/whats-going-on-with-boeing-stock-monday">What&#8217;s Going On With Boeing Stock Monday?</a>
GLYC Price Action: At the time of publication, GlycoMimetics shares are up 210.1% at 52 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image: Akava Photo from Pixabay

Movers

GlycoMimetics Shares Are Soaring Tuesday: Here's Why

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday.
The Dow traded down 0.07% to 42,357.35 while the NASDAQ rose 0.74% to 18,704.19. The S&amp;P 500 also rose, gaining, 0.34% to 5,843.35.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research">Jim Cramer: &#8216;Avoid&#8217; This Consumer Cyclical Stock, Buy Lam Research</a>
Leading and Lagging Sectors Communication services shares rose by 1.2% on Tuesday.
In trading on Tuesday, utilities shares fell by 1.6%.
Top Headline
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported better-than-expected results for its third quarter.
The company posted third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ago, beating the consensus of 62 per share. The U.S. drugmaker reported sales of $17.70 billion, up 31% year-over-year (up 32% operationally), beating the consensus of $14.95 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares shot up 161% to $0.4352 after the company announced it will merge with Crescent Biopharma and secured $200 in funding to advance its oncology pipeline.</li>
<li>Shares of BIO-key International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) got a boost, surging 95% to $1.3100 after the company announced it received a $910K order from a long-time financial services customer to upgrade its biometric customer identification technology.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares were also up, gaining 47% to $82.32 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) shares dropped 66% to $0.4235 after the company priced an $11.1 million public offering at $1.26 per unit.</li>
<li>Shares of TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) were down 30% to $87.89 after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue guidance with its midpoint below estimates.</li>
<li>Janus International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBI#NYSE">JBI</a>) was down, falling 28% to $7.45 after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded up 0.2% to $67.51 while gold traded up 1% at $2,782.00.
Silver traded up 1.9% to $34.630 on Tuesday, while copper rose 0.1% to $4.3650.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.37%, Germany's DAX fell 0.18% and France's CAC 40 slipped 0.29%. Spain's IBEX 35 Index fell 0.74%, while London's FTSE 100 fell 0.52%.
Retail sales in Spain rose by 4.1% year-over-year in September, while retail sales volumes in the UK fell by 6% in October following a 4% increase in September.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index gaining 0.49%, China's Shanghai Composite Index falling 1.08% and India's BSE Sensex surging 0.45%.
Hong Kong&#8217;s trade deficit shrank to $53.2 billion in September from $64.6 billion in the year-ago month.
Economics
<ul>
<li>The number of job openings declined by 418,000 to 7.443 million in September versus a revised 7.861 million in the previous month and below market estimates of 7.99 million.</li>
<li>The FHFA house price index rose 0.3% in August, above market estimates of a 0.2% rise.</li>
<li>The S&amp;P CoreLogic Case-Shiller home price index rose 5.2% year-over-year in August versus a 5.9% gain in July.</li>
<li>U.S. wholesale inventories declined by 0.1% month-over-month to $905 billion in September compared to revised 0.2% gain in the earlier month.</li>
<li>The U.S. trade deficit increased to $108.2 billion in September from the $94.2 billion gap in the previous month.</li>
<li>The Dallas Fed general business activity index for Texas&#8217; service sector climbed to 2 in October compared to a reading of -2.6 in the prior month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41598309/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Intraday Update

Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views

<h3>Gainers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock moved upwards by 189.9% to $0.49 during Tuesday's regular session. The market value of their outstanding shares is at $31.4 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 51.9% to $1.99. The company's market cap stands at $4.4 million. </li>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares increased by 48.0% to $82.97. The market value of their outstanding shares is at $2.2 billion. As per the press release, Q3 earnings came out today. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares moved upwards by 28.9% to $0.43. The company's market cap stands at $6.3 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 25.54% to $1.67. The market value of their outstanding shares is at $4.9 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock rose 24.08% to $7.42. The market value of their outstanding shares is at $17.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares decreased by 31.6% to $86.3 during Tuesday's regular session. The company's market cap stands at $2.8 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) shares declined by 22.97% to $7.85. The market value of their outstanding shares is at $130.3 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock fell 21.05% to $3.49. The market value of their outstanding shares is at $12.8 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares fell 19.83% to $0.25. The market value of their outstanding shares is at $7.6 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares decreased by 19.66% to $1.39. The market value of their outstanding shares is at $2.5 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock declined by 17.47% to $0.59. The market value of their outstanding shares is at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

BBLG

BIOR

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

COYA

ENSC

LIXT

LUCY

SHPH

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded mixed this morning, with the Dow Jones index edging lower on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.04% to 42,370.65 while the NASDAQ rose 0.06% to 18,577.63. The S&amp;P 500 also fell, dropping, 0.05% to 5,820.82.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research">Jim Cramer: &#8216;Avoid&#8217; This Consumer Cyclical Stock, Buy Lam Research</a>
Leading and Lagging Sectors Communication services shares rose by 0.5% on Tuesday.
In trading on Tuesday, utilities shares fell by 1.6%.
Top Headline
McDonald's Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) posted better-than-expected third-quarter earnings on Tuesday.
The company reported third-quarter adjusted earnings per share of $3.23, beating the analyst consensus estimate of $3.20. Quarterly sales of $6.90 billion beat the analyst consensus view of $6.82 billion. Revenues increased 3% (2% in constant currencies) over the prior year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares shot up 211% to $0.5292 after the company announced it will merge with Crescent Biopharma and secured $200 in funding to advance its oncology pipeline.</li>
<li>Shares of BIO-key International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) got a boost, surging 99% to $1.3104 after the company announced it received a $910K order from a long-time financial services customer to upgrade its biometric customer identification technology.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares were also up, gaining 40% to $1.85 after the company announced it finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine.</li>
</ul>
Equities Trading DOWN
<ul>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) shares dropped 65% to $0.4426 after the company priced an $11.1 million public offering at $1.26 per unit.</li>
<li>Shares of Hanryu Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRYU#NASDAQ">HRYU</a>) were down 43% to $0.2893.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) was down, falling 42% to $10.99.</li>
</ul>
Commodities In commodity news, oil traded up 0.3% to $67.61 while gold traded up 0.8% at $2,778.10.
Silver traded up 1.7% to $34.580 on Tuesday, while copper fell 0.1% to $4.3625.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 slipped 0.2%, Germany's DAX fell 0.1% and France's CAC 40 slipped 0.1%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 fell 0.4%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index gaining 0.49%, China's Shanghai Composite Index falling 1.08% and India's BSE Sensex surging 0.45%.
Economics
<ul>
<li>The number of job openings declined by 418,000 to 7.443 million in September versus a revised 7.861 million in the previous month and below market estimates of 7.99 million.</li>
<li>The FHFA house price index rose 0.3% in August, above market estimates of a 0.2% rise.</li>
<li>The S&amp;P CoreLogic Case-Shiller home price index rose 5.2% year-over-year in August versus a 5.9% gain in July.</li>
<li>U.S. wholesale inventories declined by 0.1% month-over-month to $905 billion in September compared to revised 0.2% gain in the earlier month.</li>
<li>The U.S. trade deficit increased to $108.2 billion in September from the $94.2 billion gap in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41598309/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

HRYU

PGHL

US Stocks Mixed; McDonald's Posts Upbeat Earnings

WIIM

GlycoMimetics shares are trading higher after the company announced it will merge with Crescent Biopharma and secured $200 in funding to advance its oncology pipeline.

<h3>Gainers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock rose 147.9% to $0.42 during Tuesday's pre-market session. The market value of their outstanding shares is at $26.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 56.39% to $2.08. The market value of their outstanding shares is at $6.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 55.73% to $2.04. The market value of their outstanding shares is at $4.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock increased by 52.83% to $0.84. The company's market cap stands at $4.1 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock increased by 29.53% to $2.5. The market value of their outstanding shares is at $14.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock increased by 22.44% to $0.69. The market value of their outstanding shares is at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock declined by 23.6% to $96.46 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 19.18% to $0.25. The market value of their outstanding shares is at $7.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock decreased by 16.97% to $3.67. The company's market cap stands at $13.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares decreased by 15.01% to $1.87. The company's market cap stands at $17.7 million. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) stock decreased by 14.41% to $8.5. The company's market cap stands at $127.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 13.08% to $1.13. The market value of their outstanding shares is at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMWL

HCTI

IMRN

PTIX

TRIB

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares increased by 147.9% to $0.42 during Tuesday's pre-market session. The company's market cap stands at $26.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 56.39% to $2.08. The market value of their outstanding shares is at $6.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock rose 55.73% to $2.04. The company's market cap stands at $4.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock rose 52.83% to $0.84. The market value of their outstanding shares is at $4.1 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares moved upwards by 29.53% to $2.5. The company's market cap stands at $14.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 22.44% to $0.69. The market value of their outstanding shares is at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares declined by 23.6% to $96.46 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.2 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares declined by 19.18% to $0.25. The company's market cap stands at $7.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares decreased by 16.97% to $3.67. The company's market cap stands at $13.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock fell 15.01% to $1.87. The company's market cap stands at $17.7 million. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares fell 14.41% to $8.5. The market value of their outstanding shares is at $127.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 13.08% to $1.13. The company's market cap stands at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<ul>
<li>Following closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors</li>
<li>Crescent's lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26</li>
<li>Crescent pipeline also includes two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003</li>
<li>Concurrent financing of approximately $200 million anticipated to fund operations through 2027</li>
<li>Companies to hold a conference call on Tuesday October 29, at 8:00am EDT</li>
</ul>

GlycoMimetics To Merge with Crescent Biopharma, Secures $200M Funding To Advance Oncology Pipeline

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

GlycoMimetics Says Phase 2 Analysis Of Adaptive Phase 2/3 Study Of Uproleselan Did Not Meet Primary Endpoint

Management

GlycoMimetics Anticipates Recognizing About $3.6M In Total Charges In Connection With Headcount Reduction, A Restructuring That Includes A Reduction In Company's Workforce By 26 Employees, Or ~80% Of Its Headcount

TD Cowen analyst Boris Peaker downgrades GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) from Buy to Hold.

Downgrades

Analyst Ratings

TD Cowen Downgrades GlycoMimetics to Hold

GlycoMimetics To Conduct Additional Clinical Trial For Uproleselan In R/R Acute Myeloid Leukemia After FDA Meeting; Initiates Strategic Review And Corporate Restructuring, Reducing Workforce By 80%; Engages Lucid Capital Markets As Strategic Advisor; Advancing Phase 2/3 Study Of Uproleselan In Newly Diagnosed AML Patients With NCI And Alliance For Clinical Trials; Cash Expected To Fund Company Into Q2 2025

On June 21, GlycoMimetics Got Notice From Nasdaq, Co Is Not In Compliance With Nasdaq's Listing Rule 5450(a)(1)

GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock is moving higher Monday after its chief medical officer disclosed the <a href="https://www.benzinga.com/quote/GLYC/insider-trades">purchase of company stock. </a>
The Details: On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305,000 shares of the company.
Rock purchased the shares at an average price of 26 cents.
How To Buy GlycoMimetics Stock
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/GLYC">GlycoMimetics</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 21.91%, you'll need to buy a share of Simplify Exchange Traded Funds Simplify Propel Opportunities ETF by the Jun. 25, 2024. Once done, you can expect to receive a nominal payout of $1.25 on Jun. 28, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/GLYC">GlycoMimetics</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
Related Link: <a href="http://Related Link: 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More">5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More</a>
GLYC Price Action: At the time of publication, GlycoMimetics shares is trading 20% higher at 32 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 8676549 from Pixabay.

Why GlycoMimetics Stock is Trading Higher Monday

GlycoMimetics shares are trading higher after the company disclosed that Chief Medical Officer Edwin Rock bought 305,000 shares at an average price of $0.26 per share.

Insider Trades

GlycoMimetics Form 4 Filing Shows CMO Edwin Rock Bought 305,000 Shares At An Average Price Of $0.26/Share

GlycoMimetics to cut workforce by about 80% in corporate restructuring plan

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on GlycoMimetics (GLYC – Research Report). The company's sha...

H.C. Wainwright Remains a Hold on GlycoMimetics (GLYC)

GlycoMimetics (GLYC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Naureen Quibria from C...

GlycoMimetics: Strategic Overhaul and FDA Setback Justify Hold Rating

GlycoMimetics (GLYC – Research Report) received a Hold rating and price target from TD Cowen analyst Tara Bancroft today. The company's shares clos...

GlycoMimetics (GLYC) was downgraded to a Hold Rating at TD Cowen

GlycoMimetics (GLYC) just unveiled an update. GlycoMimetics, Inc. is implementing a new operating plan to enhance shareholder value, which includes...

GlycoMimetics Announces Strategic Review and Restructuring Plan

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Doximity (DOCS – Research Report), Avinger (AVGR –...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Avinger (AVGR) and GlycoMimetics (GLYC)

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

GlycoMimetics enters acquisition agreement with Crescent Biopharma

GlycoMimetics (GLYC) announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer Institute...

GlycoMimetics: NCI Phase 2/3 study of uproleselan did not meet primary endpoint

GlycoMimetics skyrockets on buyout deal

ABUS

ALPMF

ALPMY

ANTX

ATHA

AVGR

BAYRY

BAYZF

BBIO

BMRN

CDTX

CRBU

CVAC

DOCS

FGEN

HLVX

IBRX

INAB

LXRX

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

VIRX

Press Releases

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders

Comments

GlycoMimetics

GlycoMimetics (GLYC) Opciones

GlycoMimetics (NASDAQ:GLYC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL